Ceftibuten Hydrate, CAS number 118081-34-8, is a cephalosporin antibiotic. Used as a treatment for bacterial infections such as bronchitis and ear infections, ceftibuten can also be found by it’s brand name, Cedax. Cedax is manufactured by Pernix Therapeutics, who purchased the drug in March 2010 from Shionogi Pharma Inc. Ceftibuten is an effective third generation cephalosporin treatment for patients, and LGM Pharma is a provider of the API ceftibuten for research and development.
Offered as 200 and 400 milligram capsules, or as a suspension of 90 milligrams/ 5 milliliters, ceftibuten has proven it’s efficacy in treating a variety of bacterial infections. In addition to the aforementioned bronchitis and Otitis Media, ceftibuten is extremely successful for the treatment of tonsillitis, pharyngitis, cystitis, sinusitis and pneumonia. In clinical trials ceftibuten was shown to be safe, without incidence of permanent disabilities or loss of life. In one large trial 1,728 adult patients were given a 400 milligram capsule of Cedax once daily for ten days, and only 2% of participants opted to discontinue treatment before completion of the trial. This small percentage of trial participants opted out due to adverse side effects related to gastrointestinal issues, such as diarrhea and nausea. Side effects may occur with treatment of ceftibuten, such as nausea, upset stomach, vomiting and diarrhea.
Physicians who prescribe ceftibuten to patients need to inquire with patients if they have an allergy to cephalosporins, or may be taking anticoagulants, have kidney or liver disease. Ceftibuten should be taken with a full glass of water, with or without food. In addition, patients should let their provider know if they are taking vitamins or supplements, as this could interfere with the efficacy of ceftibuten. Medications that reduce stomach acid, like Tagmet, can also interfere with the effectiveness of this antibiotic.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.